

Resource Summary Report

Generated by [dkNET](#) on Aug 19, 2026

Cyclin D2 (D52F9) Rabbit mAb

RRID:AB_2070685

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3741, RRID:AB_2070685

Antibody Information

URL: http://antibodyregistry.org/AB_2070685

Proper Citation: Cell Signaling Technology Cat# 3741, RRID:AB_2070685

Target Antigen: Cyclin D2 (D52F9) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10426893, AB_10830736, AB_2070685.

Antibody Name: Cyclin D2 (D52F9) Rabbit mAb

Description: This monoclonal targets Cyclin D2 (D52F9) Rabbit mAb

Target Organism: rat, h, m, mouse, r, human

Antibody ID: AB_2070685

Vendor: Cell Signaling Technology

Catalog Number: 3741

Record Creation Time: 20250819T234942+0000

Record Last Update: 20250820T063251+0000

Ratings and Alerts

- Used for immunocytochemistry by the Human Islet Research Network community.
Contact(s): [Peng Wang](#), [Andrew Stewart](#) - Human Islets Research Network

No alerts have been found for Cyclin D2 (D52F9) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Basili I, et al. (2026) AMBRA1 enhances Sonic Hedgehog signaling during cerebellar development and in medulloblastoma. *Developmental cell*, 61(5), 1111.

Choi PH, et al. (2026) Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer. *Cell reports*, 45(7), 117559.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. *NPJ breast cancer*, 11(1), 135.

Tang J, et al. (2025) Targeting N-Myc in neuroblastoma with selective Aurora kinase A degraders. *Cell chemical biology*, 32(2), 352.

Huang X, et al. (2025) CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 CRBN to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma. *bioRxiv : the preprint server for biology*.

Tiburcio PDB, et al. (2025) PD-L1 Expression is Mediated by microRNA Processing, Wnt/β-Catenin Signaling, and Chemotherapy in Wilms Tumor. *Pediatric blood & cancer*, 72(9), e31852.

Akatsuka H, et al. (2025) Molecular and genetic evidence for the role of AMBRA1 in suppressing S-phase entry and tumorigenesis. *iScience*, 28(8), 113054.

MacMillan AC, et al. (2025) PRPS activity tunes redox homeostasis in Myc-driven lymphoma. *Redox biology*, 84, 103649.

Tiburcio PDB, et al. (2025) Suppressing proteasome activity enhances sensitivity to actinomycin D in diffuse anaplastic Wilms tumor. *Cell reports. Medicine*, 6(5), 102133.

Tiburcio PDB, et al. (2024) Actinomycin D and bortezomib disrupt protein homeostasis in Wilms tumor. *bioRxiv : the preprint server for biology*.

Desai K, et al. (2024) PD-L1 expression is mediated by microRNA processing, Wnt/β-catenin signaling, and chemotherapy in Wilms tumor. *bioRxiv : the preprint server for biology*.

Rona G, et al. (2024) CDK-independent role of D-type cyclins in regulating DNA mismatch repair. *Molecular cell*.

Xiong L, et al. (2024) circGlis3 promotes β -cell dysfunction by binding to heterogeneous nuclear ribonucleoprotein F and encoding Glis3-348aa protein. *iScience*, 27(1), 108680.

Wang P, et al. (2024) Hepatic Snai1 and Snai2 promote liver regeneration and suppress liver fibrosis in mice. *Cell reports*, 43(3), 113875.

Mahieu CI, et al. (2024) ORAOV1, CCND1, and MIR548K Are the Driver Oncogenes of the 11q13 Amplicon in Squamous Cell Carcinoma. *Molecular cancer research : MCR*, 22(2), 152.

Huang N, et al. (2023) DHX9-mediated pathway contributes to the malignant phenotype of myelodysplastic syndromes. *iScience*, 26(6), 106962.

Wurm AA, et al. (2023) Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity. *Cell reports. Medicine*, 4(10), 101200.

Müller L, et al. (2023) Plakophilin 3 facilitates G1/S phase transition and enhances proliferation by capturing RB protein in the cytoplasm and promoting EGFR signaling. *Cell reports*, 42(1), 112031.

Arora M, et al. (2023) Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity. *Cell*, 186(12), 2628.

Baldelli E, et al. (2022) Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach. *Cell reports methods*, 2(8), 100271.